Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Febuxostat (Teijin/Ipsen/TAP).

Brian Tomlinson1

  • 1Division of Clinical Pharmacology, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, SAR China. btomlinson@cuhk.edu.hk

Current Opinion in Investigational Drugs (London, England : 2000)
|November 30, 2005
PubMed
Summary

Febuxostat is a novel oral medication targeting gout by inhibiting xanthine oxidase. Development faced delays in Japan due to further clinical trial requirements, impacting its market launch timeline.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

Importance and Management of Non-High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment.

JACC. Asia·2026
Same author

Pharmacological management of elevated LDL in patients with hypercholesterolemia and mixed dyslipidaemia.

Expert opinion on pharmacotherapy·2026
Same author

Comparing rosuvastatin and atorvastatin on cardiovascular and kidney outcomes in patients with diabetes across chronic kidney disease stages: an emulated target trial in China.

EClinicalMedicine·2026
Same author

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.

The New England journal of medicine·2025
Same author

Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β pathway.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Area of Science:

  • Pharmacology
  • Gout Treatment
  • Drug Development

Background:

  • Febuxostat is an oral, non-purine, selective inhibitor of xanthine oxidase (NP-SIXO).
  • It is being developed for the potential treatment of gout.
  • Development is a collaboration between Teijin, Ipsen, and TAP Holdings.

Purpose of the Study:

  • To provide an update on the development status of Febuxostat.
  • To report on the expected timelines for regulatory filings and market launch.

Main Methods:

  • Information gathered from industry reports and announcements.
  • Monitoring of development progress and regulatory submission schedules.

Main Results:

  • Febuxostat's development for gout treatment is ongoing.
  • A February 2005 report indicated a multi-year delay for the Japanese launch due to additional clinical trial needs.
  • An EU filing was anticipated by the end of 2005.

Conclusions:

  • Febuxostat's path to market, particularly in Japan, faced significant delays.
  • Regulatory submissions in Europe were planned for late 2005, suggesting ongoing development efforts.

Related Experiment Videos